Teva and Sanofi's experimental drug, duvakitug, demonstrated significant efficacy in a Phase 2 trial for inflammatory bowel disease, with around 50% of ulcerative colitis patients and 48% of Crohn’s disease patients showing symptom resolution compared to placebo. The companies plan to advance to late-stage development, highlighting duvakitug's potential as a leading treatment in a competitive market. Following the promising results, Teva's shares surged nearly 20%, while Sanofi's rose by almost 5%.
